ea0063s14.2 | Innovations in NETs | ECE2019
Sorbye Halfdan
Background: Peptide receptor radionuclide therapy (PRRT) is an established treatment of metastatic low-grade and intermediate-grade neuroendocrine tumors (G1-G2). However, its possible benefit in high-grade gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN G3: NET G3 and NEC) has been unknown.Methods: Data from 3 recent retrospective studies (Thang et al. 2018, Zhang et al. 2018, Carlsen et al. 2019) on efficacy and to...